Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein
Identifieur interne : 000638 ( PascalFrancis/Checkpoint ); précédent : 000637; suivant : 000639Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein
Auteurs : Bruno Jr Sainz [États-Unis] ; Joshua M. Rausch [États-Unis] ; William R. Gallaher [États-Unis] ; Robert F. Garry [États-Unis] ; William C. Wimley [États-Unis]Source :
- Journal of virology [ 0022-538X ] ; 2005.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) is a newly identified member of the family Coronaviridae and poses a serious public health threat. Recent studies indicated that the SARS-CoV viral spike glycoprotein is a class I viral fusion protein. A fusion peptide present at the N-terminal region of class I viral fusion proteins is believed to initiate viral and cell membrane interactions and subsequent fusion. Although the SARS-CoV fusion protein heptad repeats have been well characterized, the fusion peptide has yet to be identified. Based on the conserved features of known viral fusion peptides and using Wimley and White interfacial hydrophobicity plots, we have identified two putative fusion peptides (SAItSWW-I and SARSWW-II) at the N terminus of the SARS-CoV S2 subunit. Both peptides are hydrophobic and rich in alanine, glycine, and/or phenylalanine residues and contain a canonical fusion tripeptide along with a central proline residue. Only the SARSWW-I peptide strongly partitioned into the membranes of large unilamellar vesicles (LUV), adopting a β-sheet structure. Likewise, only SA========Rgr;SWW-I induced the fusion of LUV and caused membrane leakage of vesicle contents at peptide/lipid ratios of 1:50 and 1:100, respectively. The activity of this synthetic peptide appeared to be dependent on its amino acid (aa) sequence, as scrambling the peptide rendered it unable to partition into LUV, assume a defined secondary structure, or induce both fusion and leakage of LUV. Based on the activity of SA========Rgr;SWW-I, we propose that the hydrophobic stretch of 19 aa corresponding to residues 770 to 788 is a fusion peptide of the SARS-CoV S2 subunit.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:05-0250065Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein</title><author><name sortKey="Sainz, Bruno Jr" sort="Sainz, Bruno Jr" uniqKey="Sainz B" first="Bruno Jr" last="Sainz">Bruno Jr Sainz</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Immunology, Program in Molecular Pathogenesis and Immunity, Tulane University Health Sciences Center</s1><s2>New Orleans, Louisiana 70112</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New Orleans, Louisiana 70112</wicri:noRegion></affiliation></author><author><name sortKey="Rausch, Joshua M" sort="Rausch, Joshua M" uniqKey="Rausch J" first="Joshua M." last="Rausch">Joshua M. Rausch</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Biochemistry, Tulane University Health Sciences Center</s1><s2>New Orleans, Louisiana 70112</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New Orleans, Louisiana 70112</wicri:noRegion></affiliation></author><author><name sortKey="Gallaher, William R" sort="Gallaher, William R" uniqKey="Gallaher W" first="William R." last="Gallaher">William R. Gallaher</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center</s1><s2>New Orleans, Louisiana 70112</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New Orleans, Louisiana 70112</wicri:noRegion></affiliation></author><author><name sortKey="Garry, Robert F" sort="Garry, Robert F" uniqKey="Garry R" first="Robert F." last="Garry">Robert F. Garry</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Immunology, Program in Molecular Pathogenesis and Immunity, Tulane University Health Sciences Center</s1><s2>New Orleans, Louisiana 70112</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New Orleans, Louisiana 70112</wicri:noRegion></affiliation></author><author><name sortKey="Wimley, William C" sort="Wimley, William C" uniqKey="Wimley W" first="William C." last="Wimley">William C. Wimley</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Biochemistry, Tulane University Health Sciences Center</s1><s2>New Orleans, Louisiana 70112</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New Orleans, Louisiana 70112</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">05-0250065</idno><date when="2005">2005</date><idno type="stanalyst">PASCAL 05-0250065 INIST</idno><idno type="RBID">Pascal:05-0250065</idno><idno type="wicri:Area/PascalFrancis/Corpus">000673</idno><idno type="wicri:Area/PascalFrancis/Curation">000317</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000638</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000638</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein</title><author><name sortKey="Sainz, Bruno Jr" sort="Sainz, Bruno Jr" uniqKey="Sainz B" first="Bruno Jr" last="Sainz">Bruno Jr Sainz</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Immunology, Program in Molecular Pathogenesis and Immunity, Tulane University Health Sciences Center</s1><s2>New Orleans, Louisiana 70112</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New Orleans, Louisiana 70112</wicri:noRegion></affiliation></author><author><name sortKey="Rausch, Joshua M" sort="Rausch, Joshua M" uniqKey="Rausch J" first="Joshua M." last="Rausch">Joshua M. Rausch</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Biochemistry, Tulane University Health Sciences Center</s1><s2>New Orleans, Louisiana 70112</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New Orleans, Louisiana 70112</wicri:noRegion></affiliation></author><author><name sortKey="Gallaher, William R" sort="Gallaher, William R" uniqKey="Gallaher W" first="William R." last="Gallaher">William R. Gallaher</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center</s1><s2>New Orleans, Louisiana 70112</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New Orleans, Louisiana 70112</wicri:noRegion></affiliation></author><author><name sortKey="Garry, Robert F" sort="Garry, Robert F" uniqKey="Garry R" first="Robert F." last="Garry">Robert F. Garry</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Immunology, Program in Molecular Pathogenesis and Immunity, Tulane University Health Sciences Center</s1><s2>New Orleans, Louisiana 70112</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New Orleans, Louisiana 70112</wicri:noRegion></affiliation></author><author><name sortKey="Wimley, William C" sort="Wimley, William C" uniqKey="Wimley W" first="William C." last="Wimley">William C. Wimley</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Biochemistry, Tulane University Health Sciences Center</s1><s2>New Orleans, Louisiana 70112</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New Orleans, Louisiana 70112</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Journal of virology</title><title level="j" type="abbreviated">J. virol.</title><idno type="ISSN">0022-538X</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of virology</title><title level="j" type="abbreviated">J. virol.</title><idno type="ISSN">0022-538X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Coronavirus</term><term>Identification</term><term>Microbiology</term><term>Peptides</term><term>Protein</term><term>Severe acute respiratory syndrome</term><term>Virology</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Coronavirus</term><term>Identification</term><term>Peptide</term><term>Protéine</term><term>Microbiologie</term><term>Virologie</term><term>Syndrome respiratoire aigu sévère</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) is a newly identified member of the family Coronaviridae and poses a serious public health threat. Recent studies indicated that the SARS-CoV viral spike glycoprotein is a class I viral fusion protein. A fusion peptide present at the N-terminal region of class I viral fusion proteins is believed to initiate viral and cell membrane interactions and subsequent fusion. Although the SARS-CoV fusion protein heptad repeats have been well characterized, the fusion peptide has yet to be identified. Based on the conserved features of known viral fusion peptides and using Wimley and White interfacial hydrophobicity plots, we have identified two putative fusion peptides (SAItS<sub>WW-I</sub> and SARS<sub>WW-II</sub>) at the N terminus of the SARS-CoV S2 subunit. Both peptides are hydrophobic and rich in alanine, glycine, and/or phenylalanine residues and contain a canonical fusion tripeptide along with a central proline residue. Only the SARS<sub>WW-I</sub> peptide strongly partitioned into the membranes of large unilamellar vesicles (LUV), adopting a β-sheet structure. Likewise, only SA========Rgr;S<sub>WW-I</sub> induced the fusion of LUV and caused membrane leakage of vesicle contents at peptide/lipid ratios of 1:50 and 1:100, respectively. The activity of this synthetic peptide appeared to be dependent on its amino acid (aa) sequence, as scrambling the peptide rendered it unable to partition into LUV, assume a defined secondary structure, or induce both fusion and leakage of LUV. Based on the activity of SA========Rgr;S<sub>WW-I</sub>, we propose that the hydrophobic stretch of 19 aa corresponding to residues 770 to 788 is a fusion peptide of the SARS-CoV S2 subunit.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-538X</s0></fA01><fA03 i2="1"><s0>J. virol.</s0></fA03><fA05><s2>79</s2></fA05><fA06><s2>11</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein</s1></fA08><fA11 i1="01" i2="1"><s1>SAINZ (Bruno JR)</s1></fA11><fA11 i1="02" i2="1"><s1>RAUSCH (Joshua M.)</s1></fA11><fA11 i1="03" i2="1"><s1>GALLAHER (William R.)</s1></fA11><fA11 i1="04" i2="1"><s1>GARRY (Robert F.)</s1></fA11><fA11 i1="05" i2="1"><s1>WIMLEY (William C.)</s1></fA11><fA14 i1="01"><s1>Department of Microbiology and Immunology, Program in Molecular Pathogenesis and Immunity, Tulane University Health Sciences Center</s1><s2>New Orleans, Louisiana 70112</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></fA14><fA14 i1="02"><s1>Department of Biochemistry, Tulane University Health Sciences Center</s1><s2>New Orleans, Louisiana 70112</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center</s1><s2>New Orleans, Louisiana 70112</s2><s3>USA</s3><sZ>3 aut.</sZ></fA14><fA20><s1>7195-7206</s1></fA20><fA21><s1>2005</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>13592</s2><s5>354000125436420630</s5></fA43><fA44><s0>0000</s0><s1>© 2005 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>99 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>05-0250065</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Journal of virology</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) is a newly identified member of the family Coronaviridae and poses a serious public health threat. Recent studies indicated that the SARS-CoV viral spike glycoprotein is a class I viral fusion protein. A fusion peptide present at the N-terminal region of class I viral fusion proteins is believed to initiate viral and cell membrane interactions and subsequent fusion. Although the SARS-CoV fusion protein heptad repeats have been well characterized, the fusion peptide has yet to be identified. Based on the conserved features of known viral fusion peptides and using Wimley and White interfacial hydrophobicity plots, we have identified two putative fusion peptides (SAItS<sub>WW-I</sub> and SARS<sub>WW-II</sub>) at the N terminus of the SARS-CoV S2 subunit. Both peptides are hydrophobic and rich in alanine, glycine, and/or phenylalanine residues and contain a canonical fusion tripeptide along with a central proline residue. Only the SARS<sub>WW-I</sub> peptide strongly partitioned into the membranes of large unilamellar vesicles (LUV), adopting a β-sheet structure. Likewise, only SA========Rgr;S<sub>WW-I</sub> induced the fusion of LUV and caused membrane leakage of vesicle contents at peptide/lipid ratios of 1:50 and 1:100, respectively. The activity of this synthetic peptide appeared to be dependent on its amino acid (aa) sequence, as scrambling the peptide rendered it unable to partition into LUV, assume a defined secondary structure, or induce both fusion and leakage of LUV. Based on the activity of SA========Rgr;S<sub>WW-I</sub>, we propose that the hydrophobic stretch of 19 aa corresponding to residues 770 to 788 is a fusion peptide of the SARS-CoV S2 subunit.</s0></fC01><fC02 i1="01" i2="X"><s0>002A05C10</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0><s2>NW</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0><s2>NW</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0><s2>NW</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Identification</s0><s5>05</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Identification</s0><s5>05</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Identificación</s0><s5>05</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Peptide</s0><s5>06</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Peptides</s0><s5>06</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Péptido</s0><s5>06</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Protéine</s0><s5>07</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Protein</s0><s5>07</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Proteína</s0><s5>07</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Microbiologie</s0><s5>08</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Microbiology</s0><s5>08</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Microbiología</s0><s5>08</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Virologie</s0><s5>09</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Virology</s0><s5>09</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Virología</s0><s5>09</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0><s2>NM</s2><s5>14</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0><s2>NM</s2><s5>14</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0><s2>NM</s2><s5>14</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0><s5>13</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Respiratory disease</s0><s5>13</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0><s5>13</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Virose</s0></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Viral disease</s0></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Virosis</s0></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Infection</s0></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Infection</s0></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Infección</s0></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Poumon pathologie</s0><s5>16</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Lung disease</s0><s5>16</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Pulmón patología</s0><s5>16</s5></fC07><fN21><s1>171</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Sainz, Bruno Jr" sort="Sainz, Bruno Jr" uniqKey="Sainz B" first="Bruno Jr" last="Sainz">Bruno Jr Sainz</name></noRegion><name sortKey="Gallaher, William R" sort="Gallaher, William R" uniqKey="Gallaher W" first="William R." last="Gallaher">William R. Gallaher</name><name sortKey="Garry, Robert F" sort="Garry, Robert F" uniqKey="Garry R" first="Robert F." last="Garry">Robert F. Garry</name><name sortKey="Rausch, Joshua M" sort="Rausch, Joshua M" uniqKey="Rausch J" first="Joshua M." last="Rausch">Joshua M. Rausch</name><name sortKey="Wimley, William C" sort="Wimley, William C" uniqKey="Wimley W" first="William C." last="Wimley">William C. Wimley</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000638 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000638 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:05-0250065
|texte= Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein
}}
| This area was generated with Dilib version V0.6.33. |  |